Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GK21
- Development stage
- Preclinical
- Lead developer
- Zhiyi Pharmaceutics
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
GK21 is a preclinical live biotherapeutic product (LBP) being developed by Zhiyi Biotechnology. It is classified as a Class 1 Biological Product. The specific mechanism of action and the intended therapeutic indications for GK21 have not been disclosed by the company.
Beyond the preview
Go deeper on GK21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GK21.